Editas Medicine, Inc.

NasdaqGS:EDIT Lagerbericht

Marktkapitalisierung: US$270.2m

Editas Medicine Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Der Umsatz und der Gewinn von Editas Medicine werden voraussichtlich um 24.2% bzw. 8.8% pro Jahr zurückgehen. Der Gewinn je Aktie wird voraussichtlich um 2.4% pro Jahr steigen. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -88.4% betragen.

Wichtige Informationen

-8.8%

Wachstumsrate der Gewinne

2.42%

EPS-Wachstumsrate

Biotechs Gewinnwachstum25.2%
Wachstumsrate der Einnahmen-24.2%
Zukünftige Eigenkapitalrendite-88.41%
Analystenabdeckung

Good

Zuletzt aktualisiert14 May 2026

Jüngste Aktualisierungen zum künftigen Wachstum

Analyseartikel • May 08

Earnings Update: Editas Medicine, Inc. (NASDAQ:EDIT) Just Reported And Analysts Are Boosting Their Estimates

The first-quarter results for Editas Medicine, Inc. ( NASDAQ:EDIT ) were released last week, making it a good time to...
Analyseartikel • Nov 13

Analysts Are Upgrading Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results

A week ago, Editas Medicine, Inc. ( NASDAQ:EDIT ) came out with a strong set of quarterly numbers that could...

Recent updates

Analyseartikel • May 14

Analyst Forecasts Just Became More Bearish On Editas Medicine, Inc. (NASDAQ:EDIT)

The analysts covering Editas Medicine, Inc. ( NASDAQ:EDIT ) delivered a dose of negativity to shareholders today, by...
Analyseartikel • May 08

Earnings Update: Editas Medicine, Inc. (NASDAQ:EDIT) Just Reported And Analysts Are Boosting Their Estimates

The first-quarter results for Editas Medicine, Inc. ( NASDAQ:EDIT ) were released last week, making it a good time to...
Analyseartikel • Nov 13

Analysts Are Upgrading Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results

A week ago, Editas Medicine, Inc. ( NASDAQ:EDIT ) came out with a strong set of quarterly numbers that could...
Analyseartikel • Nov 05

Lacklustre Performance Is Driving Editas Medicine, Inc.'s (NASDAQ:EDIT) 29% Price Drop

Editas Medicine, Inc. ( NASDAQ:EDIT ) shares have retraced a considerable 29% in the last month, reversing a fair...
Analyseartikel • Nov 02

Here's Why We're A Bit Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Oct 14

Editas Medicine: Three Strikes And It's Out, Or Third Time's The Charm?

Summary Gene editing seems like a great idea: instead of masking the symptoms of disease, we actually change the genes to bring permanent change that actually removes the disease. The platform used nowadays to do this is known as CRISPR. I previously covered two companies, CRISPR Therapeutics and Intellia Therapeutics, that license and use this intellectual property. Editas Medicine is also a CRISPR licensee. But it failed twice, with treatments aimed at eye disease and sickle cell disease/beta thalassemia. And its stock suffered badly. With two strikes against it, EDIT is back in the batter’s box. And unlike peers that attack small-population problems, EDIT is swinging at the mass market, high LDL ("bad") cholesterol. It’s way too early to gauge potential success. But given a big target market, pioneering in-the-body editing, and a beaten-down stock, EDIT's reward-risk balance tilts toward ‘Buy.’. Read the full article on Seeking Alpha
Analyseartikel • Sep 09

Editas Medicine, Inc. (NASDAQ:EDIT) Stock Catapults 26% Though Its Price And Business Still Lag The Industry

Despite an already strong run, Editas Medicine, Inc. ( NASDAQ:EDIT ) shares have been powering on, with a gain of 26...
Analyseartikel • Jul 22

There's Reason For Concern Over Editas Medicine, Inc.'s (NASDAQ:EDIT) Massive 42% Price Jump

Editas Medicine, Inc. ( NASDAQ:EDIT ) shares have continued their recent momentum with a 42% gain in the last month...
Analyseartikel • Jun 17

Editas Medicine (NASDAQ:EDIT) Will Have To Spend Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analyseartikel • May 21

Editas Medicine, Inc.'s (NASDAQ:EDIT) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Editas Medicine, Inc. ( NASDAQ:EDIT ) shareholders are no doubt pleased to see that the share price has bounced 28% in...
Analyseartikel • Mar 30

Editas Medicine, Inc. (NASDAQ:EDIT) Looks Inexpensive After Falling 35% But Perhaps Not Attractive Enough

The Editas Medicine, Inc. ( NASDAQ:EDIT ) share price has softened a substantial 35% over the previous 30 days, handing...
Analyseartikel • Mar 13

We're A Little Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Jan 17

Editas And Intellia: Strategic Shifts And Long-Term Investment Potential

Summary Intellia Therapeutics, Inc. and Editas Medicine, Inc. are undergoing organizational restructuring and pipeline prioritization, aiming to optimize resources and extend the cash runway until 2027, despite market pessimism. Intellia's advanced clinical-stage programs and a clear path to market support a speculative “Buy” rating for long-term NTLA investors with a high-risk tolerance. Editas' in vivo CRISPR pipeline is still in the early stages, leading to a temporary “Hold” rating for EDIT stock until more clarity on targeted indications and clinical results is provided. Both companies face high risks, including potential off-target effects and market volatility, requiring cautious investment and risk mitigation strategies. Read the full article on Seeking Alpha
Analyseartikel • Nov 20

Little Excitement Around Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues As Shares Take 34% Pounding

The Editas Medicine, Inc. ( NASDAQ:EDIT ) share price has fared very poorly over the last month, falling by a...
Analyseartikel • Nov 06

Analysts Are Betting On Editas Medicine, Inc. (NASDAQ:EDIT) With A Big Upgrade This Week

Editas Medicine, Inc. ( NASDAQ:EDIT ) shareholders will have a reason to smile today, with the analysts making...
Analyseartikel • Sep 26

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Sep 25

Editas Medicine: A Risk/Reward Worth Considering

Summary Editas Medicine has made significant progress in advancing reni-cel, their in-vivo editing pipeline, and business development, despite a 65% drop in stock price. Reni-cel shows promising clinical results for sickle cell disease and beta-thalassemia, with potential BLA submission by year-end, enhancing its risk-reward profile. Editas' in-vivo pipeline and strategic partnerships bolster its position, but competition and regulatory challenges remain significant risks. EDIT's current valuation and potential market growth present an attractive investment opportunity, with a speculative yet promising outlook for long-term gains. Read the full article on Seeking Alpha
Analyseartikel • Aug 23

Benign Growth For Editas Medicine, Inc. (NASDAQ:EDIT) Underpins Stock's 32% Plummet

The Editas Medicine, Inc. ( NASDAQ:EDIT ) share price has fared very poorly over the last month, falling by a...
Analyseartikel • Aug 10

Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

As you might know, Editas Medicine, Inc. ( NASDAQ:EDIT ) last week released its latest second-quarter, and things did...
Analyseartikel • May 12

Analysts Have Lowered Expectations For Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results

As you might know, Editas Medicine, Inc. ( NASDAQ:EDIT ) last week released its latest quarterly, and things did not...
Analyseartikel • Apr 23

The Market Doesn't Like What It Sees From Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues Yet As Shares Tumble 25%

To the annoyance of some shareholders, Editas Medicine, Inc. ( NASDAQ:EDIT ) shares are down a considerable 25% in the...
Analyseartikel • Mar 09

Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement

Those holding Editas Medicine, Inc. ( NASDAQ:EDIT ) shares would be relieved that the share price has rebounded 28% in...
Seeking Alpha • Feb 28

Editas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must Watch

Summary Results from the Editas Medicine, Inc. phase 1/2 studies using reni-cel for the treatment of patients with Sickle-Cell Disease and Transfusion dependent thalassemia are expected in mid-2024 and end of 2024. The global Sickle-Cell Disease treatment market size is expected to be worth $7.79 billion by 2032. The global thalassemia treatment market is expected to reach $1.5 billion by end of 2031. Editas Medicine can overcome competition with owning several CRISPR Cas9 patents and the differentiation of using Cas12a nuclease, which might have greater selectivity and efficiency over Cas9a CRISPR candidates. Read the full article on Seeking Alpha
Analyseartikel • Dec 15

New Forecasts: Here's What Analysts Think The Future Holds For Editas Medicine, Inc. (NASDAQ:EDIT)

Editas Medicine, Inc. ( NASDAQ:EDIT ) shareholders will have a reason to smile today, with the analysts making...
Analyseartikel • May 10

Broker Revenue Forecasts For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher

Celebrations may be in order for Editas Medicine, Inc. ( NASDAQ:EDIT ) shareholders, with the analysts delivering a...

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:EDIT - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/20289-142-160N/A5
12/31/202714-126-123-11210
12/31/202614-115-115-12111
3/31/202639-109-141-141N/A
12/31/202541-160-166-165N/A
9/30/202546-200-181-180N/A
6/30/202539-237-205-201N/A
3/31/202536-251-215-208N/A
12/31/202432-237-219-210N/A
9/30/202462-211-191-182N/A
6/30/202467-193-172-165N/A
3/31/202469-166-151-146N/A
12/31/202378-153-137-132N/A
9/30/202325-195-156-152N/A
6/30/202319-206-169-165N/A
3/31/202323-219-168-164N/A
12/31/202220-220-181-177N/A
9/30/202226-201-176-170N/A
6/30/202232-184-171-162N/A
3/31/202226-186-174-164N/A
12/31/202126-193-172-164N/A
9/30/202124-214-176-169N/A
6/30/202181-167-189-183N/A
3/31/202192-135-180-175N/A
12/31/202091-116-187-180N/A
9/30/202092-91-106-99N/A
6/30/202033-132-79-71N/A
3/31/202024-142-73-66N/A
12/31/201921-134N/A-41N/A
9/30/201914-121N/A-80N/A
6/30/201925-103N/A-61N/A
3/31/201930-108N/A-52N/A
12/31/201832-110N/A-46N/A
9/30/201829-121N/A-72N/A
6/30/201821-132N/A-92N/A
3/31/201817-120N/A-102N/A
12/31/201714-120N/A-9N/A
9/30/201711-124N/A2N/A
6/30/20176-118N/A13N/A
3/31/20176-111N/A29N/A
12/31/20166-97N/A-50N/A
9/30/20166-71N/A-45N/A
6/30/20166-57N/A-39N/A
3/31/20162-86N/A-9N/A
12/31/20152-73N/A-5N/A
9/30/20151-66N/A-1N/A
6/30/20150-62N/A9N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: EDIT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: EDIT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: EDIT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: EDITDie Einnahmen des Unternehmens werden in den nächsten 3 Jahren voraussichtlich zurückgehen (-24.2% pro Jahr).

Hohe Wachstumseinnahmen: EDITDie Einnahmen des Unternehmens werden in den nächsten drei Jahren voraussichtlich zurückgehen (-24.2% pro Jahr).

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: EDIT wird voraussichtlich in 3 Jahren unrentabel sein.

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/05/25 23:51
Aktienkurs zum Tagesende2026/05/22 00:00
Gewinne2026/03/31
Jährliche Einnahmen2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Editas Medicine, Inc. wird von 25 Analysten beobachtet. 11 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Jack AllenBaird
Joel BeattyBaird
Alec StranahanBofA Global Research